2020
TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates
Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Human Immunology 2020, 81: 692-696. PMID: 32950267, DOI: 10.1016/j.humimm.2020.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAllelesBiomarkers, TumorDisease-Free SurvivalExomeGenes, T-Cell Receptor betaHead and Neck NeoplasmsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansKaplan-Meier EstimatePrognosisReceptors, Antigen, T-Cell, alpha-betaSurvival RateV(D)J RecombinationConceptsHuman papilloma virusHLA allele combinationsT cell receptorSurvival rateCervical cancerHLA allelesParticular human leukocyte antigen (HLA) allelesBetter disease-free survival rateCancer Genome Atlas (TCGA) headDisease-free survival ratesJ usageHuman leukocyte antigen (HLA) allelesFree survival rateOverall survival rateCancer survival ratesSpecific HLA allelesDistinct overall survival ratesNeck cancer datasetPapilloma virusIndependent associationAntigen presentationAntigen allelesViral infectionHLAExome files
2018
Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates
Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research And Treatment 2018, 173: 167-177. PMID: 30229447, DOI: 10.1007/s10549-018-4961-1.Peer-Reviewed Original ResearchConceptsImmune receptor recombinationsSpecific HLA allelesExome filesHLA typesBreast cancerHLA allelesSurvival rateImmune checkpoint inhibitor therapyImproved disease-free survivalDisease-free outcomeCheckpoint inhibitor therapyT cell receptor VUse of immunotherapyDisease-free survivalSegment usageB cell biomarkersBreast cancer subgroupsHLA allele combinationsBetter survival rateBreast cancer samplesBreast tumor samplesGene segment usageSurvival distinctionsInhibitor therapyImmune characterization